Medicare Negotiation
-
Word of the Year: Tangled
Read more: Word of the Year: TangledGive me time off and I’m likely to find myself in over my head with a project of my own making. #cantstopwontstop. Like deciding to bake 120 giant cookies and then deciding that I didn’t like the look of half of them and starting over. Health policy took a backseat to cookies and scones for…
-
340B, Biosimilars, Copay Accumulators, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit ManagersNot on my 2023 Bingo Card
Read more: Not on my 2023 Bingo CardWe’re in that last work week before everyone dashes off. My own clients have headed for the hills (Short Hills?) and I’ve been baking and wrapping this week. It makes me appreciate the usual day to day of policy and reimbursement more than I would have thought. Next week I’ll pull out the vision boards…
-
Caught my eye, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Pharmacy Benefit ManagersCaught my eye — 12/15/23
Read more: Caught my eye — 12/15/23Driving home (the message.) Yesterday President Biden drove up to the National Institutes of Health and gave a speech about drug prices. My main issue with it is the traffic caused by shutting down the beltway and all the roads around my neighborhood. Okay and I think that a lot of the inflation penalties for…
-
Striving toward equity in IRA negotiations
Read more: Striving toward equity in IRA negotiationsThis morning I attended the Innovation and Value Initiative’s (IVI’s) event on “Ensuring Equity in Implementation of IRA Drug Price Negotiations.” As the discussions went on, I began to believe that ensuring equity in the Inflation Reduction Act (IRA) negotiation process was too herculean. To ensure equity would require… So maybe the title of the…
-
Orphan drug: Expand the label and you lose
Read more: Orphan drug: Expand the label and you loseFrom a patient perspective, the Inflation Reduction Act (IRA) definitely has some upside. Starting in 2024, the out-of-pocket cap in the Medicare prescription drug benefit starting is fantastic for beneficiaries taking more expensive products. Although this is a minority of patients, it still gives piece of mind to many knowing that if they find themselves…
-
Caught my eye — 11/10/23
Read more: Caught my eye — 11/10/23Guess which one costs more. This Wall Street Journal article has been making the rounds this week. It highlights how if there are two prices for a drug, plans tend to prefer the higher cost one with higher rebates. I hesitate to call it news because it seems so obvious to those of us who…
-
Caught my eye — 11/3/23
Read more: Caught my eye — 11/3/23InNOvation. Seagen said they aren’t looking at a drug that would treat early-stage bladder cancer because it would be subject to negotiation too soon after approval and wouldn’t have a financial return on the investment. Today the National Pharmaceutical Council published a great piece in Health Affairs that goes deeper into the subject of innovation…
-
Caught my eye — 10/6/23
Read more: Caught my eye — 10/6/23Patients driving change. I love this story because it involves Carl Schmid, patient groups and copay accumulators. Copay accumulators are when insurance does not allow pharmaceutical manufacturer contributions to count towards patient out-of-pocket spending calculations. Thanks to the HIV+Hepatitis Policy Institute, the Diabetes Leadership Council and the Diabetes Patient Advocacy Coalition and their suit against…
-
Caught my eye — 9/29/23
Read more: Caught my eye — 9/29/23It’s not a vacation. Let’s start with federal employees; you deserve better. You often could get paid more elsewhere but you want to serve. And instead of saying thank you, Congress asks you to take a seat on the bench and (hopefully) get backpay. It feels awful and I am so sorry you have to…
-
Caught my eye — 9/22/23
Read more: Caught my eye — 9/22/23Leave the gun, take the cannoli. House Energy and Commerce hearing on Medicare price negotiation gets feisty. Not often that the mafia comes up on the House floor but an interesting comparison of price negotiation and an offer they can’t refuse. I doubt Congressman Griffith (R-VA) and I agree on much politically but on this,…
Latest news
- Caught my eye — 1/24/25
- Caught my eye — 1/16/25
- Caught my eye — 1/10/25
- Caught my eye — 12/20/24
- Nurturing the Potential of Biosimilars
Categories
- 340B (31)
- Affordable Care Act (3)
- Alzheimer's (4)
- Biosimilars (19)
- Caught my eye (53)
- Chevron Deference (2)
- CMMI (8)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (28)
- Drug shortages (7)
- DTC (2)
- Employers (7)
- Generics (4)
- Health Equity (3)
- Healthcare Costs (24)
- ICER (7)
- Importation (2)
- Inflation Reduction Act (42)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (3)
- Medicare Advantage (13)
- Medicare Negotiation (44)
- Medicare Part D (40)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (6)
- Obesity (18)
- On the Horizon (1)
- Orphan Drugs (2)
- Pharmacy Benefit Managers (25)
- Reference Pricing (4)
- State-based Reform (13)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (2)
- Value (8)